AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
UHT

Universal Health Realty Income Trust Common Stock (UHT) fair value

Real Estate · REIT - Healthcare Facilities · NYSE · United States
$37.67-0.37%
Market cap $526MNext earnings 2026-10-26Updated Oct 19, 2026
Add earnings to calendarGoogle
Our verdict
Trades 27% below our fair value
Price
$37.67
Model fair valueConfidence: medium
$51.78
Only one of our models could value this stock with confidence, so use it as a guide.
Not used by alerts or posts.
Valued as a REIT (property company): Price to FFO and EV/EBITDA comparison.
ACCE opinionUniversal Health Realty Income Trust Common Stock (UHT)
Fair value (3 models)
Not available
ACCE price target
$34.90
Rating
Not rated
Horizon
12 months
ACCE price target published on 15 Oct 2026, 00:00 CEST.
Price used: $37.67 at the close on 23 Oct 2026, 22:00 CEST.
Models: EV/EBITDA comparison and Price to FFO.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
57
out of 100
Analysts
0% buy
1 covering
P/E
26.6x
forward 38.8x
1-year return
+4.3%
Dividend yield
8.07%

Universal Health Realty Income Trust Common Stock in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

Universal Health Realty Income Trust owns and leases healthcare real estate, mostly acute care hospitals, behavioral health facilities and medical office buildings, with rent paid under long-term triple-net leases that push operating costs onto tenants. That structure explains the 94.4% gross margin and 37.9% operating margin, and it is the core of the case: contracted rent escalators provide a predictable cash stream from facilities that hospital operators cannot easily walk away from. The trade-off is growth, since revenue rose only 0.7% and the stock trades at 27.5 times trailing earnings and 38.8 times forward, a premium that needs acquisitions or rent resets to justify. With a $531M market cap and no index membership, the name is small enough to be overlooked, but its 12.5% ROE and sub-scale growth mean the valuation, not the balance sheet, is what needs testing before anyone commits capital. Score of 55/100 suggests it merits a deeper look at lease roll dates, tenant coverage and the pace of accretive acquisitions, not a conclusion yet.

AI-assisted·How I use AIWritten Oct 18, 2026
⚠ Investor warnings · 3 flagsAI-assisted·How I use AI
  • moderate
    Leverage elevated
    Debt/Equity of 2.53 is high for a balance sheet with only $49M of free cash flow against a $530M market cap.
  • moderate
    Revenue growth stalled
    Revenue grew 0.7% year over year, well below the 4.9% five-year CAGR, while earnings growth of 33.4% looks flattered by a weaker base.
  • moderate
    Price above ACCE target
    The stock trades 7.9% above the ACCE price target of $34.90, with the current price at $37.67.

AI research notes

AI-assisted·How I use AIWritten Oct 18, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
  • The dividend yield of 7.8% is a large cash return for income investors compared with most stocks.
  • Free cash flow over the last twelve months came to $49M, showing the business generates real cash.
  • A net margin of 19.1% shows the trust keeps a healthy share of each dollar of revenue as profit.
Why it could disappoint
  • Revenue grew just 0.7% over the last year, well below its 4.9% average annual pace over five years.
  • Debt to equity of 2.53 means borrowing is heavy relative to the equity cushion, which raises risk if rates or cash flows turn.
  • At 38.8 times forward earnings the shares look expensive, and the stock trades 7.9% above the ACCE price target of $34.90.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.

Next results

Oct 26, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where UHT's valuation models land
Price
$37.67
Model fair valueConfidence: medium
$51.78
Model
Fair value
Upside
EV/EBITDA comparison
Price to FFO
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

Bearish0% buy · 1 covering analyst
● Strong buy 0● Buy 0● Hold 1● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Press releases mentioning this company

Recent performance

1 week
-1.3%
1 month
-1.9%
3 months
-14.1%
6 months
-7.6%
YTD
-3.9%
1 year
+4.3%

SEC filings

Recommendation history, last 12 months

DateTypeNewPreviousPrice
15 Oct 2026, 00:00 CESTACCE price target$34.90first publication$37.81
2 Oct 2026, 00:00 CESTFair value$19.62$20.23$37.39
29 Sept 2026, 00:00 CESTFair value$20.23$20.52$38.65
26 Sept 2026, 00:00 CESTFair value$20.52$20.82$38.68
21 Sept 2026, 00:00 CESTFair value$20.82$21.16$39.79
16 Sept 2026, 00:00 CESTFair value$21.16$21.66$41.12
13 Sept 2026, 00:00 CESTFair value$21.66$22.13$40.40
5 Sept 2026, 00:00 CESTFair value$22.13$21.85$41.16
2 Sept 2026, 00:00 CESTFair value$21.85$22.31$40.98
22 Aug 2026, 00:00 CESTFair value$22.31$22.62$41.11

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full UHT page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth55Value53Quality73Momentum47Total57
Valuation
Trailing P/E
26.6x
Forward P/E
38.8x
PEG
0.80
P/B
3.76x
EV / Revenue
9.4x
Book value/sh
$10.35
Enterprise value
$929M
Profitability
ROE
12.5%
FCF yield
9.34%
ROIC
2.7%
Health and risk
Debt / equity
2.53
Dividend yield
8.07%
Beta
0.85

Price

+3.5% · 1Y

Ask anything about UHT

Answered from Universal Health Realty Income Trust Common Stock fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 0% of peers
low 0.0x26.6xhigh 26.6x
ROEbetter than 100% of peers
low -15%12%high 12%
Div yieldbetter than 67% of peers
low 0.0%8.1%high 14.0%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
UHT Universal Health Realty Income Trust Common Stock$37.67--26.6x12.5%7357
XRN Chiron Real Estate Inc. Common Stock$30.00$289% above8.1x10.4%7244
CHCT Community Healthcare Trust Incorporated Common Stock$13.00--19.0x4.9%6855
THRL.L Target Healthcare REIT Ord£1.15£227% below8.9x10.8%8571
MPT Medical Properties Trust Inc. common stock$2.70----0.6%5039
DHC Diversified Healthcare Trust Common Shares of Beneficial Interest$7.86----15.5%2632
YADR.MC Adriano Care SOCIMI, S.A.€9.95--9.3x9.5%7643

Sector report card

Where UHT ranks against its sector peers on each metric.

Computing percentiles…
  • PR Newswire•Sep 8, 2026
    UNIVERSAL HEALTH REALTY INCOME TRUST ANNOUNCES DIVIDEND
  • PR Newswire•Jul 27, 2026
    UNIVERSAL HEALTH REALTY INCOME TRUST REPORTS FINANCIAL RESULTS FOR THE THREE AND SIX-MONTH PERIODS ENDED JUNE 30, 2026
  • PR Newswire•Jun 10, 2026
    UNIVERSAL HEALTH REALTY INCOME TRUST ANNOUNCES DIVIDEND INCREASE
2 more press releases · full archive on Investor+.INVESTOR
23 filings of 40
August 2026
Aug 7
10-QQuarterly reportPeriod 2026-06-30
View on SEC →
July 2026
Jul 27
8-KCurrent reportPeriod 2026-07-27
View on SEC →
June 2026
Jun 11
Form 4Insider transactionPeriod 2026-06-10
View on SEC →
20 more filings + AI summaries on Investor+.INVESTOR